<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20151230025772N11</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-31</date_registration>
      <primary_sponsor>Zojaj Darman Toos Pharmaceutical company</primary_sponsor>
      <public_title>The preventive effect of short-term administration of a herbal combination of jujube and chamomile on the symptoms of intermittent mild asthma in children under 7 years old with viral cold.</public_title>
      <acronym></acronym>
      <scientific_title>The preventive effect of short-term administration of a herbal combination of jujube and chamomile on the symptoms of intermittent mild asthma in children under 7 years old with viral cold.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67070</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization. Sealed envelopes are used to hide the treatment. Random numbers between 0 and 1 will be generated using the calculator. Envelopes that receive codes between 0 and 0.5 will be filled with placebo and envelopes that receive codes between 0.5 and 1 will be filled with medicine. In this way, the envelopes are arranged in a random order. The envelopes are thick and opaque. Patients and physicians do not know the content of the codes until the end of the study, Blinding description: In this study, double-blind sealed packages were used to hide the treatment from doctors and patients. The doctor and patients did not know the contents of the drug or placebo package. The drug and placebo are given to the patient in the same package.</study_design>
      <phase>2-3</phase>
      <hc_freetext>asthma.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 25 children with mild intermittent asthma will be included in the study if they meet the inclusion criteria and do not have the exclusion criteria. In addition to their standard treatment, patients receive up to 2 weeks herbal drops containing chamomile and jujuba, prepared by a pharmacist and with an approved dose by a pediatric allergy and asthma specialist, at the rate of 0.5 cc per kilogram of the child's weight every 8 hours. Follow-up is done on the 3rd and 7th and 14th days by phone and according to the checklist .(The composition of the herbal drop,contains 10% of jujuba concentrate, 10% of chamomile concentrate and 80% water as solvent). Intervention 2: Control group: 25 children with mild intermittent asthma will be included in the study if they meet the inclusion criteria and do not have the exclusion criteria. In addition to their standard treatment, patients receive placebo drops for up to 2 weeks, which are completely similar to the examined drug and prepared by a pharmacist, with a dose approved by a pediatric allergy and asthma specialist, at the rate of 0.5 cc per a kilogram of the child's weight every 8 hours. Follow-up is done on the 3rd and 7th and 14th days by phone and according to the checklis .(the Placebo drop composition includes 10% starch syrup).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is It is not yet known if there will be a plan to make this available.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr.Hamid Ahanchian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahinfar Medical School , Emam Khomeini Ave.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9187147578</zip>
        <telephone>+98 51 3225 0041</telephone>
        <email>Ahanchianh@mums.ac.ir</email>
        <affiliation>Islamic Azad University of medical science mashhad branch</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Abbas Zojaji</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bo Ali Square, Mashhad University of Medical Sciences Technology Development Center</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9196773113</zip>
        <telephone>+98 51 3711 2611</telephone>
        <email>info@zojaj.club</email>
        <affiliation>Zojaj Darman Toos Pharmaceutical Company</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>children under 7 years old
Confirmation of the diagnosis of mild intermittent asthma by a pediatric immunologist based on the GINA guidelines
Having an acute respiratory viral infection</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>7 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Bacterial respiratory infection
Asthma exacerbation
History of allergy to herbal medicines
Congenital abnormalities
Any underlying disease
Lack of appropriate compliance for drug treatment
Failure to refer for follow-up</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J44</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other chronic obstructive pulmonary disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 25 children with mild intermittent asthma will be included in the study if they meet the inclusion criteria and do not have the exclusion criteria. In addition to their standard treatment, patients receive up to 2 weeks herbal drops containing chamomile and jujuba, prepared by a pharmacist and with an approved dose by a pediatric allergy and asthma specialist, at the rate of 0.5 cc per kilogram of the child's weight every 8 hours. Follow-up is done on the 3rd and 7th and 14th days by phone and according to the checklist .(The composition of the herbal drop,contains 10% of jujuba concentrate, 10% of chamomile concentrate and 80% water as solvent)</i_keyword>
      <i_keyword>Control group: 25 children with mild intermittent asthma will be included in the study if they meet the inclusion criteria and do not have the exclusion criteria. In addition to their standard treatment, patients receive placebo drops for up to 2 weeks, which are completely similar to the examined drug and prepared by a pharmacist, with a dose approved by a pediatric allergy and asthma specialist, at the rate of 0.5 cc per a kilogram of the child's weight every 8 hours. Follow-up is done on the 3rd and 7th and 14th days by phone and according to the checklis .(the Placebo drop composition includes 10% starch syrup)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cough. Timepoint: first visit , the third day, the seventh day, the fourteenth day. Method of measurement: Number of coughs per day/cough severity based on visual analog scale.</prim_outcome>
      <prim_outcome>Nighttime wakeup due to coughing. Timepoint: first visit , the third day, the seventh day, the fourteenth day. Method of measurement: amount.</prim_outcome>
      <prim_outcome>The amount of salbutamol usage. Timepoint: first visit , the third day, the seventh day, the fourteenth day. Method of measurement: number of puff per day.</prim_outcome>
      <prim_outcome>Oral corticosteroid need. Timepoint: first visit , the third day, the seventh day, the fourteenth day. Method of measurement: has/doesn't have.</prim_outcome>
      <prim_outcome>Specialist visit requierment. Timepoint: the third day, the seventh day, the fourteenth day. Method of measurement: has/doesn't have.</prim_outcome>
      <prim_outcome>Need for hospital admission. Timepoint: the third day, the seventh day, the fourteenth day. Method of measurement: has/doesn't have.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zojaj Darman Toos Pharmaceutical company</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-27</approval_date>
        <contact_name>Ethics Committee of islamic Azad university -Mashhad Branch</contact_name>
        <contact_address>Shahinfar Medical School . Imam khomeini ave. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
